Development of non-pulmonary soft-tissue metastasis is not a poor prognostic indicator in dogs with metastatic
Gabrielle S Fontes1, Kira L Bourne1, Shay Bracha1
1Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, 601 Vernon L. Tharp Sreet, Columbus, Ohio 43221, USA (Fontes, Bracha, Cook, Lapsley, Piegols, Selmic); Department of Small Animal Clinical Science, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, 660 Raymond Stotzer Pkwy, College Station, Texas 77843, USA (Bourne); Department of Clinical Sciences, Carlson College of Veterinary Medicine, Oregon State University, 700 SW 30th Street, Corvallis, Oregon 97331, USA (Curran).
Objectives:
To evaluate whether patient factors affect development of non-pulmonary soft-tissue metastases following treatment of canine appendicular osteosarcoma and to report and compare outcomes to those in dogs with pulmonary or osseous metastases.
Animals And Procedure:
The records of 3 veterinary teaching hospitals were reviewed to identify dogs that received definitive treatment for a primary appendicular osteosarcoma lesion and chemotherapy between January 2010 and June 2022. Dogs with non-pulmonary metastases following initial treatment were included. Descriptive statistics were calculated to summarize signalment information, and metastasis and survival times were compared between groups using Kaplan-Meier survival analysis and log-rank tests.
Results:
Thirty-six and 109 dogs developed non-pulmonary soft-tissue metastases and pulmonary or osseous metastases, respectively, following initial treatment. No patient factors were significantly associated with development of non-pulmonary soft-tissue metastases. The median times to non-pulmonary soft-tissue metastasis or initial pulmonary or osseous metastasis were 220 and 169 d, respectively (P = 0.18); whereas overall median survival times were 250 and 270 d, respectively (P = 0.36).
Conclusion:
Dogs with non-pulmonary soft-tissue metastases had similar disease-free intervals and survival rates to dogs with typical pulmonary or osseous metastases.
